-
ASCO 2021: TOP10 New Opportunities
Time of Update: 2021-06-12
At this ASCO meeting, MGC018 announced a dose escalation study that enrolled 29 patients covering multiple tumor types, including 3 patients with recurrent melanoma who had previously received ≥2 line checkpoint treatment .
-
Macromolecular Bioscience Hypoxia: A Double-edged Sword for Cancer Treatment
Time of Update: 2021-06-11
Macromolecular Bioscience recently published a review article "Strategies of Alleviating Tumor Hypoxia and Enhancing Tumor Therapeutic Effect by Macromolecular Nanomaterials" (https://doi.
WILEY paper information: Strategies of Alleviating Tumor Hypoxia and Enhancing Tumor Therapeutic Effect by Macromolecular NanomaterialsZhenyu Jin,Qingyu Zhao,Shanmei Yuan,Wei Jiang,Yong HuMacromolecular Bioscience DOI:org/10.
-
Gut: People with stomach problems, use this medicine with caution!
Time of Update: 2021-06-11
Grouping situation and observation time In addition, given that Helicobacter pylori (HP) is not only related to gastric ulcer and other acid-related diseases, but also the most important risk factor for gastric cancer, researchers believe that it is necessary to consider HP infection when exploring the relationship between PPI and gastric cancer The status of treatment.
-
Prof. Leiping Wang: CDK4/6 inhibitors come out surprisingly, HR+/HER2-advanced breast cancer enters a new era of targeted combined endocrine therapy
Time of Update: 2021-06-11
At present, a total of three CDK4/6 inhibitors have been approved for marketing, and seven key clinical trials of the three drugs have confirmed each other, prompting the creation of a new era of targeted endocrine therapy for HR+/HER2-advanced breast cancer.
-
The top priority for cardiotoxicity in cancer patients: full attention, full monitoring, and early diagnosis of OCC 2021
Time of Update: 2021-06-11
At the 15th Oriental Cardiology Conference (OCC 2021) Oncology and Cardiology Forum, Professor Cheng Leilei from Zhongshan Hospital of Fudan University gave professional answers and wonderful sharing on this question and related content.
-
Head-to-head superiority data presented in the global phase III head-to-head study of Zebutinib confirms the efficacy and safety advantages
Time of Update: 2021-06-11
Among them, a blockbuster study that has attracted much attention from the industry-BeiGene BTK inhibitor Baiyueze® (Zebutinib) compared to the first-generation drug Ibrutinib, used to treat relapsed or refractory (R /R) The latest head-to-head global phase III clinical study data for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) was unveiled.
-
Decei Pharma announces the latest research results of Celiniso in the treatment of relapsed and refractory multiple myeloma at the 2021 ASCO and EHA conferences｜Press Release
Time of Update: 2021-06-11
HK) dedicated to the development and commercialization of innovative tumor therapies ) Announced that the company announced at the 2021 American Society of Clinical Oncology (ASCO) annual meeting and the 2021 European Association of Hematology (EHA) conference that Celiniso and dexamethasone (Sd regimen) are used to treat relapsed and refractory multiple bone marrow in China The latest findings of the Phase II MARCH trial in patients with tumors.
-
The pain of advanced cancer patients is unbearable?
Time of Update: 2021-06-11
It is recommended to use patient-controlled analgesia (PCA): the medical staff will pre-set the dose of analgesic drugs according to the patient's pain and physical condition, and then hand it over The patient "self-management".
-
Winning at the starting point: CDE has focused on the application of biomarkers in the clinical development of anti-tumor drugs
Time of Update: 2021-06-11
June 2021 On July 2, the official website of the Center for Drug Evaluation of the National Medical Products Administration issued the "Technical Guidelines for the Application of Biomarkers in the Clinical Development of Anti-tumor Drugs (Draft for Comment)".
-
Lai Su Zhiwang Professor Zhang Xiaotian: Innovative targeted combined immunization is expected to capture the "fortress" for the treatment of advanced gastric cancer
Time of Update: 2021-06-11
The Phase II clinical trial (Abstract Number: e16040) [1] showed that the efficacy and safety of sofantinib combined with teriprizumab are excellent, and it is expected to break the treatment dilemma of patients with advanced gastric cancer.
-
Enrollment of patients in bispecific ADC solid tumor clinical trials has been completed, triggering another milestone payment for Merck
Time of Update: 2021-06-11
Recommended reading: Merck's investment in bispecific ADC reached a milestone in clinical supply to treat solid tumorsYimai Meng broke the news that the two companies reached a cooperation agreement in 2014, according to the agreement Sutro to manufacture antibodies and linkers for early clinical supply, and is eligible Get further payments and tiered privilege usage fees worldwide, as well as certain additional one-time usage fees.
-
Topic Written Talk｜Professor Zhao Changlin and Xu Huimian: Progress in comprehensive treatment of advanced gastric cancer (6) ——Progress in systemic drug therapy for recurrence or metastasis of advanced gastric cancer (2)
Time of Update: 2021-06-11
Carefully screen second and third-line gastric cancer patients with large tumor burden; (3) the efficacy and adverse reactions and drug resistance of previous drug treatments; (4) nutrition and the Eastern Cooperative Oncology Group (ECOG) activity status (PS) score; ( 5) Age, underlying diseases; (6) The willingness of patients and their families to treat and socio-economic factors, to comprehensively measure the interests of patients .
-
Innomicropharmaceuticals will announce MVR-T3011 U.S. clinical phase I intratumoral dosing data on 2021ASCO
Time of Update: 2021-06-11
The OvPENS platform includes five modules: basic research, patented technology, genetic recombination technology, production technology, and commercial analysis, enabling the preclinical and clinical research and development of a new generation of oncolytic viruses with high efficiency, safety and innovation.
-
Express reduces the risk of recurrence of renal cell carcinoma by 32%, and the phase 3 results of blockbuster PD-1 inhibitors are positive
Time of Update: 2021-06-11
"Reference: [1] Merck's KEYTRUDA® (pembrolizumab) Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC).
-
"Nature": Hypnotize tumor cells and inhibit tumor metastasis!
Time of Update: 2021-06-11
They took the liver metastasis model of breast cancer as the research object and found that in the microenvironment where tumor cells are dormant, NK cells maintain tumor cell dormancy through interferon-γ signals, and activated hepatic stellate cells can secrete chemokines.
-
Nature's three publications provide new prevention strategies for high-risk groups of colorectal cancer
Time of Update: 2021-06-11
Existing studies have shown that Apc mutations in intestinal stem cells can negatively regulate WNT signal transduction by guiding the phosphorylation and degradation of β-catenin [3], thereby uncontrollably breaking the gap between WNT agonists and antagonists Balance [4, 5], this phenomenon often induces early colorectal cancer.
-
Carefully crafted, hit the weakness!
Time of Update: 2021-06-11
The birth of trastuzumab, the top ten target among 100 monoclonal antibody drugs, has completely changed the fate of patients with HER2-positive advanced breast cancer.
-
Wu Da Zhang Xianzheng Small Methods: Self-supplied H2O2 barbed nano-drum for tumor photothermal and cascade catalytic therapy
Time of Update: 2021-06-11
Therefore, it is of great significance to design a functional carrier with high biological safety and excellent enzyme loading efficiency for protein drug delivery.
The lower toxicity, good biocompatibility and higher drug loading efficiency of nanocarriers are the key factors to solve the problem of drug delivery in the treatment of diseases.
-
NEJM editor-in-chief class: The editor-in-chief criticizes commercial interests for obstructing clinical research on new trends in tumor immunotherapy (part 2)
Time of Update: 2021-06-11
Dan Longo, the editor in charge of the New England Journal of Medicine (NEJM), to summarize the progress of tumor immunotherapy in the past three years and clarify the main lines and trends of frontier progress.
-
How should ALK and BRAF mutation-positive NSCLC patients choose treatment options?
Time of Update: 2021-06-11
Professor Han Liang discussed issues related to precise diagnosis and treatment of ALK and BRAF mutation-positive NSCLC patients.
After a reasonable targeted drug treatment, Many patients can survive for 5 years or more, so ALK fusion is also known as the "diamond mutation" of NSCLC.
